REGENCELL BIOSCIENCE (RGC) FY2025 TL;DR
Financial Status & Liquidity: RGC is an early-stage TCM developer targeting ADHD/ASD with no revenue generated. FY2025 saw a Net Loss of $3.58M, an 18% YoY improvement, driven by significant cost control (Total OpEx down to ~\(3.77M). Net Cash Used in Operations improved to (\)3.11M), but the company ended the period with low liquidity ($2.42M cash). The Accumulated Deficit widened to ($25.20M). Auditors noted substantial doubt regarding the ability to continue as a going concern without new financing. The balance sheet con
...